Talha Badar

2.2k total citations
106 papers, 642 citations indexed

About

Talha Badar is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Talha Badar has authored 106 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hematology, 43 papers in Genetics and 27 papers in Molecular Biology. Recurrent topics in Talha Badar's work include Acute Myeloid Leukemia Research (68 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (30 papers) and Chronic Myeloid Leukemia Treatments (28 papers). Talha Badar is often cited by papers focused on Acute Myeloid Leukemia Research (68 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (30 papers) and Chronic Myeloid Leukemia Treatments (28 papers). Talha Badar collaborates with scholars based in United States, Saudi Arabia and Italy. Talha Badar's co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Nirav N. Shah, Naval Daver, Mark R. Litzow, Elias Jabbour, Srđan Verstovšek and Guillermo Garcia‐Manero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Talha Badar

87 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Talha Badar United States 14 390 222 192 161 84 106 642
Mohammad Hussaini United States 14 266 0.7× 156 0.7× 171 0.9× 138 0.9× 89 1.1× 68 527
Zineb Hamilou Canada 6 408 1.0× 265 1.2× 238 1.2× 72 0.4× 51 0.6× 18 652
Yue‐Yun Lai China 14 542 1.4× 196 0.9× 256 1.3× 119 0.7× 72 0.9× 79 693
Prapti A. Patel United States 13 323 0.8× 240 1.1× 91 0.5× 156 1.0× 37 0.4× 60 532
Marie Jarošová Czechia 17 354 0.9× 264 1.2× 301 1.6× 136 0.8× 156 1.9× 87 766
Jean Michel Cayuela France 10 481 1.2× 132 0.6× 411 2.1× 149 0.9× 42 0.5× 12 727
Bashar Dabbas United States 9 221 0.6× 211 1.0× 124 0.6× 92 0.6× 80 1.0× 22 559
Michela Rondoni Italy 13 390 1.0× 123 0.6× 230 1.2× 102 0.6× 50 0.6× 42 541
Nicolas Duployez France 17 621 1.6× 375 1.7× 303 1.6× 79 0.5× 53 0.6× 67 950
Dong Wu China 14 304 0.8× 227 1.0× 129 0.7× 89 0.6× 29 0.3× 39 545

Countries citing papers authored by Talha Badar

Since Specialization
Citations

This map shows the geographic impact of Talha Badar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talha Badar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talha Badar more than expected).

Fields of papers citing papers by Talha Badar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Talha Badar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talha Badar. The network helps show where Talha Badar may publish in the future.

Co-authorship network of co-authors of Talha Badar

This figure shows the co-authorship network connecting the top 25 collaborators of Talha Badar. A scholar is included among the top collaborators of Talha Badar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Talha Badar. Talha Badar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Badar, Talha, et al.. (2025). Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms. Current Opinion in Hematology. 33(2). 51–57.
2.
Mohty, Razan, Ahmad Halwani, Talha Badar, et al.. (2025). Malignancies after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 31(11). 863–873.
3.
Patnaik, Mrinal M., Haris Ali, Eunice S. Wang, et al.. (2025). Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. PubMed. 2(4). 100115–100115.
4.
Kusne, Yael, Talha Badar, Terra L. Lasho, et al.. (2025). Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. British Journal of Haematology. 206(4). 1109–1120. 2 indexed citations
5.
Badar, Talha, Terra L. Lasho, Yael Kusne, et al.. (2024). PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations. Blood. 144(Supplement 1). 3218–3218. 1 indexed citations
6.
Badar, Talha, James M. Foran, Mohamed A. Kharfan‐Dabaja, et al.. (2024). Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series. Blood. 144(Supplement 1). 1823–1823. 1 indexed citations
7.
Tefferi, Ayalew, Giuseppe Gaetano Loscocco, Aref Al‐Kali, et al.. (2024). TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Blood. 144(Supplement 1). 244–244.
8.
Badar, Talha, Keith L. Knutson, James M. Foran, et al.. (2024). T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia. Blood Advances. 9(2). 239–243. 6 indexed citations
9.
Shahzad, Moazzam, Muhammad Kashif Amin, Naval Daver, et al.. (2024). What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer Journal. 14(1). 202–202. 15 indexed citations
10.
Badar, Talha, James M. Foran, David S. Viswanatha, et al.. (2023). Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms. Haematologica. 108(11). 3033–3043. 10 indexed citations
11.
McCullough, Kristen, Aref Al‐Kali, Hassan B. Alkhateeb, et al.. (2023). Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent. Blood. 142(Supplement 1). 2853–2853. 1 indexed citations
12.
13.
Badar, Talha, Hassan B. Alkhateeb, Mahmoud Aljurf, & Mohamed A. Kharfan‐Dabaja. (2023). Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era. Current Research in Translational Medicine. 71(2). 103392–103392. 1 indexed citations
14.
Badar, Talha, James M. Foran, Aref Al‐Kali, et al.. (2023). U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer Journal. 13(1). 149–149. 7 indexed citations
15.
Badar, Talha, et al.. (2022). Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes. Cancer Management and Research. Volume 14. 3527–3538. 7 indexed citations
16.
Alkhateeb, Hassan B., David S. Viswanatha, James M. Foran, et al.. (2021). Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms. Blood Advances. 6(2). 528–532. 27 indexed citations
17.
Badar, Talha & Ehab Atallah. (2021). Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. Expert Opinion on Investigational Drugs. 30(6). 665–673. 5 indexed citations
18.
Badar, Talha, Narendranath Epperla, Anikó Szabó, et al.. (2020). Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances. 4(1). 47–54. 13 indexed citations
19.
Badar, Talha, Anikó Szabó, David A. Sallman, et al.. (2020). Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leukemia & lymphoma. 61(6). 1418–1427. 14 indexed citations
20.
Badar, Talha, et al.. (2014). Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.. PubMed. 100(1). 75–9. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammad Hussaini Breakdown of academic impact, for papers by Zineb Hamilou Breakdown of academic impact, for papers by Yue‐Yun Lai Breakdown of academic impact, for papers by Prapti A. Patel Breakdown of academic impact, for papers by Marie Jarošová Breakdown of academic impact, for papers by Jean Michel Cayuela Breakdown of academic impact, for papers by Bashar Dabbas Breakdown of academic impact, for papers by Michela Rondoni Breakdown of academic impact, for papers by Nicolas Duployez Breakdown of academic impact, for papers by Dong Wu
Rankless by CCL
2026